Malaria is one again the number one infectious disease threatening mankind with an estimated 500 million cases worldwide and 2.3 million deaths in 1986. Of particular concern is severe anemia in children which in some malarious areas of Africa causes more pediatric deaths than cerebral malaria. Control efforts have been hampered by the emergence of insecticide resistant Anopheles mosquito vectors and of drug resistant strains of Plasmodium falciparum, the most common and deadly species infecting mankind. It has recently been suggested that an effective vaccine against asexual blood-stage forms or merozoites, which multiply in the host red blood cells and cause the clinical symptoms and pathology of malaria, would have the earliest and most dramatic impact on human morbidity and mortality. However, the immunological events resulting in control and elimination of blood-stage malaria remain incompletely understood. Although antibody-mediated immunity is considered to play a major role, the importance of cell-mediated responses, involving CD4+ T cells, macrophages and their cytokines, has recently been recognized. The studies proposed in this application are based on the hypothesis that a fulminant, lethal course of acute blood-stage malaria associated with severe anemia versus a non-lethal course is a consequence of counter- regulation by cytokines associated with CD4+ Th1 and Th2 responses. The objective of the proposed studies is to determine the role of several key immunomodulatory cytokines with counter-regulatory activities on the development of protection versus pathology during blood-stage malaria. We also propose to examine the effectiveness of a novel vaccination strategy to prevent severe and fatal malaria. The murine model of inbred mouse strains which are genetically resistant or susceptible to infection with the rodent malaria species, Plasmodium chabaudi AS, will be used to achieve these objectives.
The specific aims are: (1) to determine the role of the Th2 derived cytokines, IL4 and IL10, in the pathogenesis of severe anemia and down-regulation of protective cell-mediated immune responses during lethal blood-stage malaria; (2) to identify the role of Il12 in the generation of protective erythropoietic and immune Th1 responses in the spleen to acute blood-stage P. chabaudi AS and (3) to devise a strategy for preventing or subverting the severe and lethal consequences of malaria by vaccination with low doses of parasites, a strategy which favors the development of Th1 responses. Analysis of host defense mechanisms in the spleen, which are hypothesized to involve both extra-medullary, erythropoietic responses and activation of effector macrophages, will be carried out at the cellular and molecular levels. The rodent model of acute blood-stage P. chabaudi AS infection in well-defined inbred strains of mice, which experience either a lethal or non-lethal course of infection, should, therefore, be useful in defining the immunobiology of host-parasite interactions under genetically and environmentally controlled circumstances, conditions which are difficult to achieve in human populations.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI035955-02
Application #
2071951
Study Section
Special Emphasis Panel (SRC (40))
Project Start
1994-09-01
Project End
1997-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Montreal General Hospital
Department
Type
DUNS #
City
Montreal
State
PQ
Country
Canada
Zip Code
Stevenson, M M; Su, Z; Sam, H et al. (2001) Modulation of host responses to blood-stage malaria by interleukin-12: from therapy to adjuvant activity. Microbes Infect 3:49-59
Sam, H; Su, Z; Stevenson, M M (1999) Deficiency in tumor necrosis factor alpha activity does not impair early protective Th1 responses against blood-stage malaria. Infect Immun 67:2660-4
Mohan, K; Sam, H; Stevenson, M M (1999) Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection. Infect Immun 67:513-9
Sam, H; Stevenson, M M (1999) Early IL-12 p70, but not p40, production by splenic macrophages correlates with host resistance to blood-stage Plasmodium chabaudi AS malaria. Clin Exp Immunol 117:343-9
Sam, H; Stevenson, M M (1999) In vivo IL-12 production and IL-12 receptors beta1 and beta2 mRNA expression in the spleen are differentially up-regulated in resistant B6 and susceptible A/J mice during early blood-stage Plasmodium chabaudi AS malaria. J Immunol 162:1582-9
Mohan, K; Stevenson, M M (1998) Dyserythropoiesis and severe anaemia associated with malaria correlate with deficient interleukin-12 production. Br J Haematol 103:942-9
Mohan, K; Stevenson, M M (1998) Interleukin-12 corrects severe anemia during blood-stage Plasmodium chabaudi AS in susceptible A/J mice. Exp Hematol 26:45-52
Mohan, K; Moulin, P; Stevenson, M M (1997) Natural killer cell cytokine production, not cytotoxicity, contributes to resistance against blood-stage Plasmodium chabaudi AS infection. J Immunol 159:4990-8
Jacobs, P; Radzioch, D; Stevenson, M M (1996) In vivo regulation of nitric oxide production by tumor necrosis factor alpha and gamma interferon, but not by interleukin-4, during blood stage malaria in mice. Infect Immun 64:44-9
Stevenson, M M; Tam, M F; Wolf, S F et al. (1995) IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. J Immunol 155:2545-56